"instanceType","label","text","id","name","description","uuid:ID"
"Objective","","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective_1","OBJ1","Main objective","eda7fa4e-2440-4f15-b22d-f3e5e3285ba3"
"Objective","","To document the safety profile of the xanomeline TTS.","Objective_2","OBJ2","Safety","e0ce826e-f5c5-4ec2-8e83-840a07aa79c5"
"Objective","","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective_3","OBJ3","Behaviour","d4904a54-89a5-45d6-ae00-2fc8c769513d"
"Objective","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective_4","OBJ4","","dfdcd217-e15b-45f5-8c62-0d00edd5c231"
"Objective","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective_5","OBJ5","","47e34326-d66d-4548-a0d1-18bf3c2472c4"
"Objective","","To assess the treatment response as a function of Apo E genotype.","Objective_6","OBJ6","","29a5c8e5-17f0-4e8c-b990-3994e6a22596"
